相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Phase Ib study of oral panobinostat (LBH589) plus intravenous bortezomib in patients (Pts) with relapsed (Rel) or Rel and refractory (Ref) multiple myeloma (MM).
J. F. San-Miguel et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
PANORAMA1: A randomized, double-blind, placebo controlled phase III study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed multiple myeloma.
J. F. San-Miguel et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Interferon gamma licensing of human dendritic cells in T-helper-independent CD8+ alloimmunity
Roxane Lemoine et al.
BLOOD (2010)
In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma
Enrique M. Ocio et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Phase Ib study of oral panobinostat (LBH589) plus lenalidomide (LEN) plus dexamethasone (DEX) in patients (Pts) with relapsed (Rel) or Rel and refractory (Ref) multiple myeloma (MM)
M. Mateos et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Treatment with Panobinostat Induces Glucose-Regulated Protein 78 Acetylation and Endoplasmic Reticulum Stress in Breast Cancer Cells
Rekha Rao et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challenges
Peter Atadja
CANCER LETTERS (2009)
Histone Deacetylases Are Required for Androgen Receptor Function in Hormone-Sensitive and Castrate-Resistant Prostate Cancer
Derek S. Welsbie et al.
CANCER RESEARCH (2009)
Clinical Studies of Histone Deacetylase Inhibitors
H. Miles Prince et al.
CLINICAL CANCER RESEARCH (2009)
Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors
H. Miles Prince et al.
FUTURE ONCOLOGY (2009)
The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repair
P. Maiso et al.
LEUKEMIA (2009)
A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancer
Eric H. Rubin et al.
CLINICAL CANCER RESEARCH (2006)
Aggresome induction by proteasome inhibitor bortezomib and α-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells
Laurence Catley et al.
BLOOD (2006)
Predicting pharmacokinetic food effects using biorelevant solubility media and physiologically based modelling
Hannah M. Jones et al.
CLINICAL PHARMACOKINETICS (2006)
Anticancer activities of histone deacetylase inhibitors
Jessica E. Bolden et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Effects of food on the clinical pharmacokinetics of anticancer agents - Underlying mechanisms and implications for oral chemotherapy
BN Singh et al.
CLINICAL PHARMACOKINETICS (2004)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
分享论文
